

REMARKS

Claims 1-19 have been canceled. Claim 20 has been amended. Thus, claims 20 and 24-30 remain presented for examination. Reconsideration and withdrawal of the present rejections in view of the amendments and comments presented herein are respectfully requested.

Claim objection

Claim 20 was rejected based on duplication of the terms "dipeptidyl peptidase IV" and "somatostatin." The duplicate recitation of "dipeptidyl peptidase IV" has been deleted, as have both occurrences of "somatostatin." Thus, withdrawal of the claim objection is respectfully requested.

Rejections under 35 U.S.C. § 112

Claims 1-19 were rejected under 35 U.S.C. § 112 as failing to comply with the enablement requirement. Although applicant does not agree with the rejection, and submits that these claims are fully enabled by the specification as filed, claims 1-19 have been canceled herein, thus rendering this rejection moot.

Claims 8, 20 and 24-30 were rejected based on scope of enablement. Claim 8 has been canceled herein. Thus, the rejection will be discussed as it applies to claims 20 and 24-30. The Examiner stated that the specification was enabling for aminopeptidase, dipeptidyl peptidase IV, CD13, CD26 and CD69. Claim 20 as amended recites determining a level of antibodies to a self-tissue or peptide selected from the group consisting of an aminopeptidase, dipeptidyl peptidase IV, CD26, CD13 and CD69, all of which were acknowledged by the Examiner to be enabled. Claims 24-30 are dependent on Claim 20. Thus, reconsideration and withdrawal of the enablement rejection of claims 20 and 24-30 are respectfully requested.

Rejection under 35 U.S.C. §102(b)

Claims 1-7, 9, 11-14 and 17-19 were rejected under 35 U.S.C. § 102(b) as being anticipated by Vojdani et al. (*J. Immunol.* 129:168-177, 2002). Although Applicant does not agree with the rejection, claims 1-7, 9, 11-14 and 17-19 have been canceled solely to expedite prosecution of the application. Thus, this rejection is now moot.


CONCLUSION

Applicants submit that all claims are now in condition for allowance. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. If any minor matters remain that could be resolved by teleconference, the Examiner is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 23, 2007

By: 
Neil S. Birtfeld, Ph.D.
Registration No. 39,901
Agent of Record
Customer No. 20,995
(619) 235-8550